Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of shorter infusion duration of obinutuzumab in CD20-positive non-Hodgkin lymphoma
jRCT2080222796Phase 2Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Mar 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of obinutuzumab in non-Hodgkin lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and 1 more, sponsored by Chugai Pharmaceutical Co., Ltd. Started Mar 2015; status: completed.
02
Drugs
obinutuzumab
03
Conditions
non-Hodgkin lymphoma (NHL)diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)marginal zone B-cell lymphoma (MZL)
Beyond the preview
Go deeper on jRCT2080222796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222796.